Cytosorbents Corporation (CTSO) Covered Calls

CytoSorbents Corporation is a leader in blood purification technology, specializing in treating life-threatening conditions in the ICU and cardiac surgery. Its flagship product, CytoSorb, is an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" that causes organ failure. As of April 2026, the firm is awaiting an FDA decision on its DrugSorb-ATR system for antithrombotic removal while working to regain Nasdaq compliance.

You can sell covered calls on Cytosorbents Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CTSO (prices last updated Thu 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Technology

CytoSorbents Corporation (NASDAQ: CTSO) develops and commercializes blood purification technologies based on proprietary biocompatible, porous polymer beads. Its lead product, CytoSorb, is CE-marked and used in over 70 countries to treat sepsis, trauma, and liver failure by removing excessive inflammatory mediators. In 2026, the company launched "HotSwap™" and renewed its partnership with Aferetica, aiming for operating cash flow breakeven by the end of the year through international sales growth and high gross margins (exceeding 70%).

In the U.S. market, the primary catalyst for 2026 is the DrugSorb-ATR antithrombotic removal system. Following a de novo pre-submission meeting with the FDA in early 2026, a regulatory decision is anticipated in mid-2026. This device is designed to reduce perioperative bleeding in cardiac surgery patients taking blood thinners like ticagrelor or DOACs, addressing a significant unmet need in the cardiothoracic circuit.

Competitive Landscape and Market Risks

CTSO operates in a highly specialized medical device sector. While its polymer technology is unique, it faces competition from larger medical technology firms and traditional pharmacological reversal agents. The stock is currently under a Nasdaq 180-day extension (until September 28, 2026) to regain compliance with the $1.00 minimum bid price rule. Management has indicated that a reverse stock split remains an option to satisfy listing requirements if the organic stock price does not recover following the DrugSorb-ATR regulatory update.

Publicly traded competitors that are optionable include:

1. EDAP TMS S.A.: A medical equipment peer specializing in therapeutic ultrasound technology with high options liquidity.
2. Avita Medical, Inc.: A regenerative medicine company and small-cap peer in the medical device sector.
3. Baxter International Inc.: A diversified medical giant that competes in the broader renal and acute care blood-filtering market.
4. Inovio Pharmaceuticals, Inc.: A biotech peer frequently compared to CTSO due to similar market-cap levels and high retail trading interest.

2026 Strategic Outlook

The roadmap for the remainder of 2026 focuses on "FDA Approval and Commercial Launch." If DrugSorb-ATR receives marketing authorization, CytoSorbents expects to unlock an additional $2.5 million in credit facility funding. The company’s strategic workforce reduction in late 2025 has significantly lowered its cash burn, allowing it to maintain an interest-only period on its debt through December 31, 2026. Investors are focused on the mid-year regulatory milestone, which will likely determine the firm's ability to transition into a commercial-stage leader in the U.S. hospital market.

Want more examples? CTSH Covered Calls | CTVA Covered Calls